Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
May 10, 2024 06:00 ET
|
Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of...
Thérapeutique Knight déclare ses résultats du premier trimestre de 2024
May 09, 2024 07:30 ET
|
Thérapeutique Knight inc.
MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de...
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
May 08, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through...
Global Indexable Inserts Market Report 2024-2029: Technology and Market Overview, PCD Diamond Inserts, cBN/PcBN Inserts, Ceramic Inserts, Carbide Inserts
May 08, 2024 04:00 ET
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Indexable Inserts - Global Markets, End-Users, Applications & Competition 2024-2029" report from Dedalus Consulting has been added to ...
Ocular Therapeutix™ Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2024 20:16 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the...
CORRECTION: New York Sen. Michelle Hinchey, Emma Heming Willis Join Families of People With Frontotemporal Degeneration To Call For Increased Awareness And Research Into Underdiagnosed Disease
May 06, 2024 15:05 ET
|
Association for Frontotemporal Degeneration
Houston, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- A previous version of this press release contained an incomplete quote from Sen. Michelle Hinchey. The full, corrected quote is in the third...
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
May 06, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
May 06, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no...